Baxter International: leaders came and went.
- Industry
- Surgical & Medical Instruments & Apparatus
- Headquarters
- United States
- Ticker
- BAX (NYSE)
- Sources
- SEC filings (1994–2026), Stratrix's verified Decision Cases, market data and official economic statistics for the United States
- Data as of
- November 2, 2026
- Leaders came and went. Baxter International filed 41 leadership changes since 2016, more than 93% of large manufacturers (the median is 20). The day after each, its shares moved a median 0.1 points against its sector. The news was rarely news.
Financial results
| Fiscal year | Revenue | Net income | |
|---|---|---|---|
| 2016 | $10.2 billion | $5 billion | |
| 2017 | $10.6 billion | $0.6 billion | |
| 2018 | $11.1 billion | $1.5 billion | |
| 2019 | $11.4 billion | $1 billion | |
| 2020 | $11.7 billion | $1.1 billion | |
| 2021 | $12.1 billion | $1.3 billion | |
| 2022 | $10.1 billion | −$2.4 billion | |
| 2023 | $10.4 billion | $2.7 billion | |
| 2024 | $10.6 billion | −$0.6 billion | |
| 2025 | $11.2 billion | −$1 billion |
As reported in its annual filings. Losses in red.
Has Baxter International had layoffs?
Job cuts, severance and restructuring
None of Baxter International’s annual reports for 2023 to 2025 describes a layoff, workforce reduction or restructuring.
| Fiscal year ended | Restructuring charges |
|---|---|
| 2016-12-31 | $285 million |
| 2017-12-31 | $70 million |
| 2018-12-31 | $117 million |
| 2019-12-31 | $134 million |
| 2020-12-31 | $111 million |
| 2021-12-31 | $91 million |
| 2022-12-31 | $144 million |
| 2023-12-31 | $141 million |
| 2024-12-31 | $146 million |
| 2025-12-31 | $162 million |
Baxter International has filed no restructuring notice (Form 8-K, Item 2.05) since 2016. Companies file one only for a cut they judge material, so many announced layoffs never appear as one. This page shows what the company reported to the SEC, not news reports or state layoff notices.
What has Baxter International acquired?
Deals its annual reports describe
| Business | Deal | When | Value |
|---|---|---|---|
Kidney Care business (Vantive Health LLC), sold to Carlyle“On January 31, 2025, we completed the sale of our Kidney Care business to Carlyle for an aggregate purchase price of $3.80 billion in cash, subject to certain closing cash, working capital and debt adjustments.” 10-K for 2024 | divestiture | On January 31, 2025, we completed the sale of our Kidney Care business to Carlyle | aggregate purchase price of $3.80 billion in cash |
BioPharma Solutions (BPS) business“On September 29, 2023, we completed the sale of our BPS business and received cash proceeds of $3.96 billion from that transaction.” 10-K for 2024 | divestiture | On September 29, 2023 | cash proceeds of $3.96 billion |
Hillrom Holdings, Inc.“We acquired Hillrom on December 13, 2021 and recognized $6.83 billion of goodwill and $6.03 billion of other intangible assets, including $1.91 billion of indefinite-lived intangible assets, in connection with that acquisition.” 10-K for 2024 | acquisition | December 13, 2021 | — |
Zosyn rights from a subsidiary of Pfizer Inc.“Under the terms of the acquisition, we paid the acquisition price of $122 million and received specified intellectual property, including patent rights, in the first quarter of 2022 and received additional intellectual property, including the product rights to Zosyn, in the first quarter of 2023.” 10-K for 2024 | acquisition | — | acquisition price of $122 million |
Kidney Care business (now Vantive Health LLC)“On January 31, 2025, we completed the sale of our Kidney Care business to Carlyle for an aggregate purchase price of $3.80 billion in cash, subject to certain closing cash, working capital and debt adjustments.” 10-K for 2025 | divestiture | January 31, 2025 | $3.80 billion in cash |
Hillrom“In addition, we acquired Hillrom in 2021 and continue to work to fully integrate it into our business.” 10-K for 2025 | acquisition | 2021 | — |
| Fiscal year ended | Cash paid for acquisitions (net of cash acquired) | Goodwill from acquisitions |
|---|---|---|
| 2016-12-31 | $48 million | $3 million |
| 2017-12-31 | $686 million | $303 million |
| 2018-12-31 | $268 million | $32 million |
| 2019-12-31 | $418 million | $111 million |
| 2020-12-31 | $494 million | $34 million |
| 2021-12-31 | $10.5 billion | $6.79 billion |
| 2022-12-31 | $258 million | — |
| 2023-12-31 | $4 million | — |
| 2024-12-31 | $14 million | — |
| 2025-12-31 | $9 million | — |
Deal filings since 2016
- 2026-08-18 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2025-12-04 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2025-11-25 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2025-06-12 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2025-02-03 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2024-08-13 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2024-07-18 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2024-03-21 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2023-10-02 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2023-05-09 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2023-03-13 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2022-09-30 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2021-12-13 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2021-12-02 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2021-11-17 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2021-10-04 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2021-09-02 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2020-11-06 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2020-03-27 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-12-20 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-10-09 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2018-01-08 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2016-03-24 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2016-01-11 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
Who are Baxter International's competitors?
Who Baxter International names
Baxter International’s annual reports for 2023 to 2025 describe its competition by kind of business and do not name competing companies.
Who names Baxter International
Companies whose own annual reports name Baxter International as a competitor.
“On a product basis, competitors include Evoqua, IsoPure, Baxter and Steris.” 10-K for 2020
“Larger companies such as Johnson & Johnson, Baxter International, Medtronic and Hologic have offerings that compete with our medical device products.” 10-K for 2025
“We compete with products and systems marketed by Becton Dickinson ("BD"), Baxter International ("Baxter"), B. Braun Medical, Inc.” 10-K for 2025
“On a product basis, competitors include 3M, Baxter, Boston Scientific, Belimed, Ecolab, Fortive, Getinge, Karl Storz, Olympus, Ruhof, SteelCo, Stryker, Skytron and Wassenburg.” 10-K for 2026
“We are one of five leading global competitors in Medical; the other four being Baxter International Inc., Zoll Medical Corporation, Medline Industries and Ferno-Washington, Inc.” 10-K for 2025
Layoffs, acquisitions, competitors and subsidiaries are read from Baxter International’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023), as of 2026-02-12.
Everything behind these findings, ready for your board deck.
- Market reaction to disclosed decisions: 72 decision filings since 2016, each linked to the SEC, with the share return against its sector and the US market the next day and the next year (47 with market data).
- Economic context: 7 measures for the United States, every year since 2016, from the official sources.
- Peer comparison: against 264 companies of its size in its sector.
- Financial results: ten years of revenue, operating and net income, and every annual report, linked.
- Methods and sources, so each number can be checked and cited.
The full data sheet downloads with the Data Plan. To see exactly what you get first, open the Boeing sample PDF or Excel.
More from Stratrix
The Business Model Wizard
Make the seven choices that define your model, test your numbers against real companies, and meet the rival AI would build against you.
Free · about twelve minutesBuild your Model Thesis →Test a decision, free
Set a live decision against the companies that made it before you.
AcquisitionsThe Distance TestDivestituresThe Divestiture TestDiversificationThe Diversification TestMake or buyThe Make-or-Buy TestWeekly email
Stratonomics, every Tuesday
One data story every Tuesday: what happened, what it means, and the figures you can quote. Free.